OncoMed Provides Update on Navicixizumab Partnership
20 sept. 2018 08h00 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ: OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
OncoMed to Present at Two Upcoming Investor Conferences in September
29 août 2018 16h00 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
OncoMed Announces Second Quarter 2018 Financial Results and Operational Highlights
02 août 2018 08h00 HE
|
OncoMed Pharmaceuticals, Inc.
-Company prioritizes its navicixizumab resources in platinum-resistant ovarian cancer; prepares to share data in Q4 of 2018- -Cash runway extended by an additional quarter to YE 2019- REDWOOD CITY,...
OncoMed Doses First Patient in Phase 1b Portion of anti-TIGIT Clinical Trial
12 juin 2018 08h00 HE
|
OncoMed Pharmaceuticals, Inc.
Expanded Phase of Trial will Assess anti-TIGIT in Combination with anti-PD1 REDWOOD CITY, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage...
OncoMed Announces First Quarter 2018 Financial Results and Operational Highlights
08 mai 2018 16h05 HE
|
OncoMed Pharmaceuticals, Inc.
Q1 Cash Balance of $88.4 Million—Cash through Q3 2019 First patient expected to be dosed in Phase 1b portion of anti-TIGIT trial in second quarter of 2018 Navicixizumab data expected in second half...
OncoMed Pharmaceuticals to Report First Quarter 2018 Financial Results and Operational Highlights on May 8th, 2018
01 mai 2018 07h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer...
OncoMed Presents Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting
18 avr. 2018 09h01 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
OncoMed to Present Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting
09 avr. 2018 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., April 09, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
OncoMed Announces Appointment of John Lewicki, PhD, as President, Chief Executive Officer and a member of the Board of Directors
19 mars 2018 08h32 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
OncoMed Announces Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights
08 mars 2018 16h15 HE
|
OncoMed Pharmaceuticals, Inc.
Navicixizumab and anti-TIGIT data expected in the 2nd Half of 2018 Management to Host Conference Call/Webcast this afternoon at 4:30 p.m. ET / 1:30 p.m. PT REDWOOD CITY, Calif., March 08, 2018 ...